At a glance
| Trade context | Decorinyl |
|---|---|
| Development concept | Decorin-mimetic collagen organization |
| Naming detail | Original paper describes a tetrapeptide |
| Laboratory endpoint | Collagen fibrillogenesis |
| Human evidence | Small randomized formulation study |
Overview
Decorin is a natural extracellular-matrix component involved in collagen organization. Tripeptide-10 citrulline was developed to reproduce a small part of that interaction, rather than to replace the entire decorin protein. Its naming deserves clarification: the INCI ingredient name contains tripeptide, while the original development report describes an engineered tetrapeptide. This is a useful example of why ingredient names alone are not a complete structural description. Cosmetic claims focus on collagen-fiber organization and skin suppleness. They should be distinguished from claims of increasing total collagen, treating connective-tissue disease, or delivering a medically proven regenerative effect.
How it works
The original work screened short sequences for binding-related effects on collagen fibrillogenesis. The selected ingredient altered collagen-fibril formation in vitro, consistent with the proposed decorin-mimetic concept. Organizing fibers is a different hypothesis from simply increasing collagen quantity. Whether a topical product delivers enough active peptide to reproduce that effect in living human skin requires evidence beyond the isolated laboratory assay.
From fibril assay to a small human study
The 2008 development report identified the ingredient through collagen-fibrillogenesis experiments. A later randomized study assigned twenty-four volunteers to formulations containing this peptide, acetyl hexapeptide-3, both, or neither. Some surface-topography and water-loss measures differed over sixty days. With approximately six participants per group, precision and generalizability remain limited.
What the findings do not establish
The human study did not clearly resolve whether the two peptides acted synergistically. Surface appearance and water-loss measurements also do not directly demonstrate rearrangement of collagen fibers deep in the dermis. The laboratory mechanism and human cosmetic outcomes should therefore be connected as a hypothesis, not presented as a fully proven causal chain.
Cosmetic assessment and formulation limits
Cosmetic status is not FDA drug approval. A small study is insufficient to define uncommon adverse effects or long-term use, and evidence from one vehicle does not establish performance in every product. The data do not support extrapolation to injection, systemic connective-tissue repair, or treatment of a medical skin disorder.
Reading this profile
Jurisdiction: United States; status and indications may differ elsewhere. Molecular class: Synthetic decorin-mimetic tetrapeptide with an INCI tripeptide name.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Decorin-like peptide development and in vitro collagen-fibril organization ↗Original research · Checked 2026-10-27
- Tripeptide-10 citrulline and acetyl hexapeptide-3: randomized cosmetic study ↗Clinical trial source · Checked 2026-10-27
- FDA: authority over cosmetics and the distinction from drug approval ↗Regulatory source · Checked 2026-10-27